Insiders Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Market Closed - Nasdaq Other stock markets 21:00:00 15/05/2024 BST			5-day change	1st Jan Change
3.48 ^USD	-4.40%		-9.14%	-15.94%

05-08	Transcript : Relmada Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
05-08	Relmada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Relmada Says Chief Medical Officer Leaving; Names Senior Clinical Development Advisor	01-04	MT
Relmada Therapeutics, Inc. Announces Resignation of Cedric O?Gorman as Chief Medical Officer	01-03	CI
Relmada Therapeutics, Inc. Announces Eric Schmidt to Resign from the Board, Chairman of the Audit Committee of the Board and as A Member of the Corporate Governance and Nominating Committee of the Board	06/09/23	CI
Relmada Therapeutics, Inc. Appoints Fabiana Fedeli to Board of Directors	12/01/23	CI
Relmada Therapeutics, Inc. Appoints Cedric O'Gorman MD as Chief Medical Officer	09/01/23	CI
Nurosene Health Names Chief Innovation and Regulatory Officer	22/07/22	MT
Relmada Therapeutics, Inc. Appoints John Hixon as Head of Commercial	21/07/22	CI
Insider Trends: Insider 90-Day Selling Trend Extended at Relmada Therapeutics	16/07/21	MT
Insider Trends: Insider Prolongs 90-Day Selling Trend at Relmada Therapeutics	02/06/21	MT
Insider Trends: Insider Prolongs Selling Trend at Relmada Therapeutics	05/05/21	MT
Insider Trends: Relmada Therapeutics Sees 90 Days of Insider Buying Trend Interrupting with Share Sale	05/04/21	MT
Insider Trends: 90-Day Insider Selling Trend Extended at Relmada Therapeutics	02/02/21	MT
Relmada Therapeutics, Inc. Announces Resignation of Thomas Wessel as Executive Vice President and Head of Research and Development	05/01/21	CI
Relmada Therapeutics Announces Appointments of New Executive	27/10/20	CI
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations	26/05/20	CI
Relmada Therapeutics, Inc. Appoints Marc de Somer, Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety	31/03/20	CI
Relmada Therapeutics, Inc. Announces Management Changes	09/03/20	CI
Relmada Therapeutics, Inc. Announces Management Changes	10/01/20	CI
Relmada Therapeutics, Inc. Announces Management Changes	20/12/19	CI
Relmada Therapeutics, Inc. Appoints Charles S. Ence, as Chief Financial Officer	29/07/19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Relmada Therapeutics, Inc.

Equities

RLMD

US75955J4022

Insiders

Filters